**Core Concept**
The question is testing the understanding of prodrugs, which are inactive compounds that undergo metabolic conversion to their active forms. In the context of antiplatelet drugs, prodrugs are used to enhance bioavailability, reduce toxicity, or improve pharmacokinetics.

**Why the Correct Answer is Right**
Clopidogrel is a prodrug that is metabolized by the cytochrome P450 enzyme system, specifically CYP2C19, to its active metabolite, which inhibits the P2Y12 receptor on platelets. This receptor is crucial for platelet aggregation, and its inhibition prevents thrombus formation. The prodrug form of clopidogrel is more lipophilic, allowing it to cross the blood-brain barrier and be more effectively absorbed.

**Why Each Wrong Option is Incorrect**
**Option A:** Aspirin is not a prodrug; it is an irreversible inhibitor of COX-1, which leads to the production of thromboxane A2 and inhibits platelet aggregation.
**Option B:** Prasugrel is an active drug, not a prodrug; it directly inhibits the P2Y12 receptor without the need for metabolic conversion.
**Option C:** Ticagrelor is an active drug that directly inhibits the P2Y12 receptor; it does not undergo metabolic conversion to an active form.

**Clinical Pearl / High-Yield Fact**
Clopidogrel is often used in conjunction with aspirin for patients at high risk of cardiovascular events, such as those with acute coronary syndromes or undergoing coronary stenting.

**Correct Answer:** C. Prasugrel is an active drug, not a prodrug; it directly inhibits the P2Y12 receptor without the need for metabolic conversion.